Danielle Brill
Stock Analyst at Truist Financial
(4.78)
# 553
Out of 4,512 analysts
379
Total ratings
56.6%
Success rate
17.2%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgraded: Buy | $235 | $193.55 | +21.42% | 18 | Jul 13, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $200 | $171.22 | +16.81% | 23 | Jul 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $560 | $479.51 | +16.79% | 8 | Jul 13, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | n/a | $281.85 | - | 15 | Jul 10, 2026 | |
| ARGX argenx SE | Maintained: Buy | n/a | $868.33 | - | 32 | Jun 24, 2026 | |
| IRON Disc Medicine | Maintained: Buy | n/a | $75.43 | - | 18 | Jun 16, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | n/a | $98.19 | - | 8 | Jun 15, 2026 | |
| PRAX Praxis Precision Medicines | Rated: Buy | $715 → $616 | $316.34 | +94.73% | 2 | Jun 2, 2026 | |
| CLYM Climb Bio | Maintained: Buy | n/a | $13.15 | - | 4 | Jun 2, 2026 | |
| APGE Apogee Therapeutics | Rated: Hold | $81 | $133.95 | -39.53% | 4 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $23 → $30 | $38.52 | -22.11% | 14 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $145.59 | - | 12 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.04 | - | 2 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 | $39.85 | +40.53% | 2 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $185 | $109.71 | +68.63% | 8 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $43 | $7.06 | +509.07% | 6 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $29.66 | - | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $34.76 | +72.64% | 11 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 | $82.34 | +23.88% | 14 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $25 → $29 | $34.64 | -16.27% | 19 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $9.08 | $41.98 | n/a | 23 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $12.63 | n/a | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $25.31 | n/a | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $79 | $58.42 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $150 | $18.39 | n/a | 36 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $80.60 | n/a | 21 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $39.90 | n/a | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 → $50 | $67.05 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $22.60 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.42 | n/a | 19 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $10 | $4.57 | n/a | 5 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $12.60 | n/a | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $10.76 | n/a | 2 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $51.31 | n/a | 10 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $231.39 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $5 | $15.49 | n/a | 5 | Nov 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $130.77 | n/a | 1 | Jul 26, 2016 |
Biogen
Jul 13, 2026
Upgraded: Buy
Price Target: $235
Current: $193.55
Upside: +21.42%
Neurocrine Biosciences
Jul 13, 2026
Maintained: Buy
Price Target: $200
Current: $171.22
Upside: +16.81%
Vertex Pharmaceuticals
Jul 13, 2026
Maintained: Buy
Price Target: $560
Current: $479.51
Upside: +16.79%
Alnylam Pharmaceuticals
Jul 10, 2026
Maintained: Buy
Price Target: n/a
Current: $281.85
Upside: -
argenx SE
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $868.33
Upside: -
Disc Medicine
Jun 16, 2026
Maintained: Buy
Price Target: n/a
Current: $75.43
Upside: -
Dianthus Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: n/a
Current: $98.19
Upside: -
Praxis Precision Medicines
Jun 2, 2026
Rated: Buy
Price Target: $715 → $616
Current: $316.34
Upside: +94.73%
Climb Bio
Jun 2, 2026
Maintained: Buy
Price Target: n/a
Current: $13.15
Upside: -
Apogee Therapeutics
May 28, 2026
Rated: Hold
Price Target: $81
Current: $133.95
Upside: -39.53%
May 22, 2026
Maintained: Hold
Price Target: $23 → $30
Current: $38.52
Upside: -22.11%
May 21, 2026
Maintained: Buy
Price Target: n/a
Current: $145.59
Upside: -
May 19, 2026
Maintained: Buy
Price Target: n/a
Current: $6.04
Upside: -
May 19, 2026
Maintained: Buy
Price Target: $56
Current: $39.85
Upside: +40.53%
May 18, 2026
Maintained: Buy
Price Target: $185
Current: $109.71
Upside: +68.63%
May 14, 2026
Maintained: Buy
Price Target: $43
Current: $7.06
Upside: +509.07%
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $29.66
Upside: -
May 11, 2026
Maintained: Buy
Price Target: $60
Current: $34.76
Upside: +72.64%
May 11, 2026
Reiterated: Buy
Price Target: $102
Current: $82.34
Upside: +23.88%
May 8, 2026
Maintained: Hold
Price Target: $25 → $29
Current: $34.64
Upside: -16.27%
Dec 10, 2024
Maintained: Buy
Price Target: $20 → $9.08
Current: $41.98
Upside: n/a
Nov 18, 2024
Reiterated: Buy
Price Target: $18
Current: $12.63
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $25.31
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $79
Current: $58.42
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $150
Current: $18.39
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $80.60
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $39.90
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $52 → $50
Current: $67.05
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $22.60
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $7.42
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $24 → $10
Current: $4.57
Upside: n/a
Jun 30, 2021
Initiated Coverage: Hold
Price Target: n/a
Current: $12.60
Upside: n/a
May 27, 2020
Maintained: Buy
Price Target: $35 → $45
Current: $10.76
Upside: n/a
Feb 13, 2020
Maintained: Hold
Price Target: n/a
Current: $51.31
Upside: n/a
Dec 16, 2019
Reiterated: Buy
Price Target: $125
Current: $231.39
Upside: n/a
Nov 7, 2019
Maintained: Hold
Price Target: $6 → $5
Current: $15.49
Upside: n/a
Jul 26, 2016
Downgraded: Hold
Price Target: n/a
Current: $130.77
Upside: n/a